Segment Reporting

3 Months Ended

Oct. 31, 2023

Segment Reporting [Abstract]

Segment reporting

Note 12 - Segment reporting

The Company has one reportable segment, Products, which develops, manufactures, and markets products to research and pharmaceutical customers. The Company evaluates segment performance based on segment income (loss) before taxes. Costs excluded from segment income (loss) before taxes and reported as “Corporate & Other” consist of corporate general and administrative costs which are not allocable to the Products segment.

Legal and related expenses incurred to defend the Company’s intellectual property, which may result in settlements recognized in another segment and other general corporate matters are considered a component of the Corporate & Other segment. Legal and related expenses specific to the Products’ segment’s activities are allocated to that segment.

Management of the Company assesses assets on a consolidated basis only and therefore, assets by reportable segment have not been included in the reportable segments below. The accounting policies of the reportable segment are the same as those described in the summary of significant accounting policies.

The following financial information represents the operating results of the reportable segments of the Company:

Three months ended October 31, 2023

	Products			Corporate & Other			Consolidated
Revenues	$	7,806			—		$	7,806
Operating costs and expenses:
Cost of revenues		4,351			—			4,351
Research and development		838		$	11			849
Selling, general and administrative		3,104			3,903			7,007
Legal and related expenses		30			1,045			1,075
Total operating costs and expenses		8,323			4,959			13,282
Operating loss		(517	)		(4,959	)		(5,476	)
Other income (expense)
Interest		34			943			977
Change in fair value of convertible debentures		—			(328	)		(328	)
Other		2			156			158
Foreign exchange loss		(1,006	)		—			(1,006	)
Loss before taxes	$	(1,487	)	$	(4,188	)	$	(5,675	)
Depreciation and amortization included above	$	166		$	104		$	270
Share-based compensation included above:
Selling, general and administrative		22			1,047			1,069
Cost of sales		6			—			6
Total	$	28		$	1,047		$	1,075
Capital expenditures	$	248		$	6		$	254

Three months ended October 31, 2022

	Products			Corporate & Other			Consolidated
Revenues	$	7,103			—		$	7,103
Operating costs and expenses:
Cost of revenues		4,589			—			4,589
Research and development		690		$	9			699
Selling, general and administrative		2,885			2,552			5,437
Legal and related expenses		25			982			1,007
Total operating costs and expenses		8,189			3,543			11,732
Operating loss		(1,086	)		(3,543	)		(4,629	)
Other income (expense)
Interest		25			47			72
Other		2			(2	)		—
Foreign exchange loss		(797	)		—			(797	)
Loss before taxes	$	(1,856	)	$	(3,498	)	$	(5,354	)
Depreciation and amortization included above	$	165		$	83		$	248
Share-based compensation included above:
Selling, general and administrative		20			340			360
Cost of sales		6			—			6
Total	$	26		$	340		$	366
Capital expenditures	$	306		$	183		$	489